NCT03583697: A reported trial by BioMarin Pharmaceutical
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03583697 |
|---|---|
| Title | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia, Age 0 to < 60 Months |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 13, 2018 |
| Completion date | Jan. 26, 2022 |
| Required reporting date | Jan. 26, 2025, midnight |
| Actual reporting date | Nov. 14, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |